Advertise on podcast: JACC Specialty Journals

Rating

★★★★☆

3.8

from

19 reviews

Description

In this podcast series, editors-in-chief from the JACC family of specialty journals provide highlights and summarize key findings for select issues. Published by the American College of Cardiology, the JACC Journals publish peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance, state-of-the art papers, and review articles. They are top ranked for impact factor and their manuscripts are among the most covered by media outlets, most talked about on social media, and most read online.

Unlock JACC Specialty Journals podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Social media

Check JACC Specialty Journals social media presence

Podcast episodes

Check latest episodes from JACC Specialty Journals podcast

Plasma Proteins Associated with Incident Acute Myocardial Infarction in Asians with Type 2 Diabetes | JACC: Asia

2026/11/03

Commentary by Dr. Athanasios Sakalidis.

Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan | JACC: Asia

2026/11/03

Commentary by Dr. Heerajnarain Bulluck.

Multimodality Imaging-Based Phenotyping and Prognostic Implications of Right Ventricular Involvement in Apical Hypertrophic Cardiomyopathy | JACC: Asia

2026/11/03

Commentary by Dr. Milan Prsa.

Osteosarcopenia as a Risk Factor for Atrial Fibrillation: A Multi-Cohort Study | JACC: Asia

2026/11/03

Commentary by Dr. Yuhi Fujimoto.

Epidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia | JACC: Asia

2026/11/03

Commentary by Dr. Yoshihiro Miyamoto.

Advances in a Capsule: October 2026 | JACC: Advances

2026/10/29

Audio Summary of three articles from the October 2026 issue of JACC: Advances.

XGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: Asia

2026/10/20

Commentary by Dr. Yoriyasu Suzuki.

Design and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: Asia

2026/10/20

Commentary by Dr. Junjie Yang.

Prediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: Asia

2026/10/20

Commentary by Dr. Qinkai Yu.

October 2026 Summary | JACC: CardioOncology

2026/10/20

Editor-in-Chief Dr. Bonnie Ky introduces the October 2026 issue of JACC: CardioOncology, featuring Part 1 of a special focus on immunology and cardio-oncology. This issue brings together state-of-the-art reviews, primers, original research, and clinical cases examining the immune system's central role in cancer and cardiovascular disease. Topics include the mechanisms and clinical implications of cancer immunotherapies and the immune system's contributions to the cardiovascular effects of cytotoxic chemotherapy, with implications for scientific discovery and patient care.

Fibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncology

2026/10/20

Dr. Caitlin O'Meara discusses a JACC: CardioOncology study showing that doxorubicin reprograms CD8+ T cells into matrix-remodeling T cells (mxT-cells) that produce lysyl oxidase (LOX) and stiffen the cardiac extracellular matrix through HIF1α-P53-TGFβ signaling. She explains how this new immune mechanism of anthracycline cardiotoxicity could lead to therapies that prevent cardiac fibrosis, cardiomyopathy, and heart failure in patients treated with chemotherapy.

High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncology

2026/10/20

Dr. David Austin discusses a JACC: CardioOncology study showing that high-sensitivity cardiac troponin T was elevated in 37.9% of patients starting immune checkpoint inhibitor (ICI) therapy, compared with only 1.8% for high-sensitivity troponin I, a discordance linked to older age, male sex, and kidney dysfunction. He explains what this means for troponin assay selection, baseline testing, and ICI myocarditis surveillance, helping cardiologists and oncologists avoid unnecessary cancer treatment interruptions and immunosuppression.

Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis | JACC: CardioOncology

2026/10/20

Dr. Cristina Gil-Cruz discusses a JACC: CardioOncology study comparing early- and late-manifestation immune checkpoint inhibitor (ICI) myocarditis, where endomyocardial biopsies showed greater T-cell and macrophage infiltration in early cases despite similar left ventricular ejection fraction and fibrosis. She explains what these inflammatory cell profiles mean for cardio-oncology care, from immunosuppression and ICI rechallenge to balancing cardiac safety with effective cancer immunotherapy.

Impact of Device Position and Aortic Valve Prolapse on Outcomes After Transcatheter VSD Closure | JACC: Asia

2026/10/07

Commentary by Dr. Timothy Un.

Prognostic Impact of Residual Thrombus After Aspiration Thrombectomy in ST-Elevation Myocardial Infarction | JACC: Asia

2026/10/07

Commentary by Dr. Ziyad Ghazzal.

Podcast reviews

Read JACC Specialty Journals podcast reviews

3.8 out of 5

19 reviews

★★★★★

Medical podcast fan. 2023/06/07

JACC specialty podcast

JACC specialty podcasts are getting more numerous and higher in quality. This requires a lot of work in time, so the efforts are commendable. Podcasts...

check all reviews on apple podcasts